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Abstract 
 
Objective 
Treatment resistance complicates the management of schizophrenia. Research and 
clinical translation is limited by inconsistent definitions. To address this we evaluated 
current approaches and then developed consensus criteria and guidelines. 
 
Method 
A systematic review of randomized antipsychotic clinical trials in treatment resistant 
schizophrenia was performed. Definitions of treatment resistance were extracted. 
Subsequently, consensus operationalized criteria were developed by a working 
group of researchers and clinicians through i) a multi-phase, mixed methods 
approach; ii) identifying key criteria via an online survey; and iii) meetings to achieve 
consensus. 
 
Results 
42 studies met inclusion criteria. Of these, 21 (50%) studies did not provide 
operationalized criteria, whilst in others, criteria varied considerably, particularly 
regarding symptom severity, prior treatment duration and antipsychotic dose 
thresholds. Important for the inability to compare results, only two (5%) studies 
utilized the same criteria. The consensus group identified minimum and optimal 
criteria, employing the following principles: 1) current symptoms of a minimum 
duration and severity determined by a standardized rating scale; 2) ≥moderate 
functional impairment; 3) prior treatment consisting of ≥2 different antipsychotic trials, 
each for a minimum duration and dose; 4) adherence systematically assessed and 
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meeting minimum criteria; 5) ideally at least one prospective treatment trial; 6) 
criteria that clearly separated responsive from treatment resistant patients. 
 
Conclusions 
There is considerable variation in current approaches to defining treatment 
resistance in schizophrenia. We present consensus guidelines that operationalize 
criteria for determining and reporting treatment resistance, adequate treatment and 
treatment response in schizophrenia, providing a benchmark for research and 
clinical translation.  
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Introduction 
Schizophrenia is a severe mental disorder characterized by positive, negative and 
cognitive symptoms (1). The treatment of schizophrenia was revolutionized by the 
introduction of chlorpromazine in the 1950s (2). However, it rapidly became clear 
that some patients showed little if any clinical response despite treatment with 
multiple different antipsychotic drugs, with the sole exception of clozapine (3). In 
1988, clozapine was shown to be effective where other antipsychotic drugs had 
failed (4), crystallizing the concept that in a proportion of patients schizophrenia is 
treatment resistant to most antipsychotics. 
 
There has been a considerable amount of research into treatment resistance, and its 
management, which has formed a key component of treatment guidelines around the 
world (5–8). However, studies have used a variety of different approaches to defining 
treatment resistance, such that patients included in one study could be excluded 
from another, as illustrated in figure 1 (9).   
 
Consequently, comparing studies may be akin to comparing apples to oranges. This 
is a major hindrance to the field; making the interpretation of meta-analyses difficult, 
and potentially contributing to failures to replicate findings. For example, a recent 
network meta-analysis concluded clozapine was no more efficacious than other 
second-generation antipsychotics for treatment resistant schizophrenia (10), in 
contrast to an earlier meta-analysis by the same group that excluded studies focused 
only on treatment resistant patients (11).  
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Direct comparisons with the same intervention are also affected. For example, Bitter 
et al (12) found olanzapine to be efficacious; whilst Buchanan et al. (13) found no 
benefit for it. Heterogeneity of study designs and populations, including less 
restrictive definitions of resistance (see figure 1), may contribute to these 
inconsistencies (14). 
 
This lack of uniformity in the definition of treatment resistance also impacts clinical 
guidelines that seek to distil the evidence from studies. Not surprisingly, given the 
variation in criteria us d in the studies, treatment guidelines use vague definitions 
that are open to a wide range of interpretations (see table 1), potentially leading to 
inconsistent clinical management and treatment delays(15; 16). 
 
In view of this situation, the Treatment Response and Resistance in Psychosis 
(TRRIP) working group was formed to establish consensus criteria to standardize the 
definition of treatment resistance. The aim was to develop criteria to aid study design 
and facilitate comparison of results from different studies. These recommendations 
are not intended to restrict research using other criteria. However, by providing a 
consensus benchmark, it will be possible to specify how studies using other criteria 
differ from the consensus criteria, and to investigate to what degree this might 
influence results. 
 
General requirements for treatment resistance 
Several factors were considered in developing the criteria. First, there is the need for 
the criteria to encompass a core definition of treatment resistance that captures the 
worldwide understanding of the concept. Second, the criteria need to be applicable 
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across a range of study designs, extending from longitudinal clinical trials and 
experimental medicine studies, to cross-sectional mechanistic investigations. Third, 
the criteria need to identify a group of patients who are clearly distinct from non-
resistant patients. Finally, there is the need for the criteria to be practical, so that 
they can be used in a wide range of settings, but still rigorous. 
 
Three key elements define the concept of treatment resistant schizophrenia. These 
are: 1) a confirmed diagnosis of schizophrenia based on validated criteria; 2) 
adequate pharmacological treatment; and 3) persistence of significant symptoms 
despite this treatment. We recognize that the optimal approach to determining lack of 
treatment response would be identifying patients at their first psychotic episode and 
prospectively assessing their response to sequential adequate treatment trials. 
However, this is unlikely to be practical for the majority of studies, and would be 
infeasible for identifying the many patients who develop resistance after years of 
treatment. In view of this fact, criteria need to also allow for cross-sectional 
identification of treatment resistance. 
 
However, the risk of false positives is likely to be greater with the cross-sectional 
identification of treatment resistance than with prospective determination. This is 
because cross-sectional identification requires the retrospective determination of 
response and adequacy of treatment, and is dependent on potentially less reliable 
sources of information, such as case-notes and patient or informant report data. 
Whilst recognizing that with any approach there is a risk of false positives, it is 
important to have criteria that are sufficiently rigorous to capture the construct, yet 
also practical enough to enable studies to be conducted. In view of this we present 
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two sets of criteria: minimum and optimum criteria. The optimum criteria are to be 
used where possible; particularly in clinical trials and hypothesis testing where the 
false positive rate should be low. The minimum criteria might be used for initial 
studies and hypothesis generation where there are practical limitations on study 
design and some false positives can be accepted. 
  
 
Methods 
An iterative approach was adopted to develop criteria for treatment resistance in 
schizophrenia. Initially, a systematic review of definitions of treatment resistant 
schizophrenia used in clinical trials was conducted. A literature search of PubMed, 
PsycINFO, and Embase from January 1980 to January 2016 was undertaken using 
the search string: “(randomized or random or randomly) and (resistant or refractory 
or clozapine) and (schizophrenia)”. Titles and abstracts were reviewed to initially 
determine eligibility. The reference lists of each relevant paper were also searched, 
as were reference lists of relevant review papers, to further identify potential studies. 
Studies were included if they were randomized controlled trials of a pharmacological 
intervention in adults with treatment resistant schizophrenia. Studies were excluded 
if they were naturalistic, or purely of biomarkers such as neuroimaging measures, 
studies of adjuvant treatments or non-pharmacological interventions, studies of 
childhood onset or late onset schizophrenia. 
 
The data extracted were: the prerequisites for previous antipsychotic treatment 
(requirements of different antipsychotics, minimum treatment duration, dose); the 
specified severity of symptoms; and whether there was a stipulation for resistance to 
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be prospectively demonstrated. Additionally, whether criteria were operationalized or 
not was recorded. To be considered as operationalized, the study had to report 
criteria that met the following characteristics: 1) The use of a validated rating scale to 
determine symptom severity; 2) A specification of minimum symptom duration; and 
3) A definition of adequate treatment that specified minimum dose, duration, and 
number of previous antipsychotics. 
 
Subsequently, a working group - consisting of expert researchers and clinicians, 
scientists from the pharmaceutical industry and other specialists with experience and 
expertise in the area of schizophrenia - was identified by the co-chairs of the 
Treatment Response and Resistance in Psychosis working group (OH, JMK, CUC). 
This was augmented by attendees at TRRIP meetings held at international 
conferences in the field. Members of the final working group included researchers 
who had published recently in the field and researchers who attended the inaugural 
TRRIP meeting at the Schizophrenia International Research Society Biennial 
meeting in 2014. The working group mapped out the key criteria and operationalized 
them.  
 
Second, members of the TRRIP working group were contacted and invited to take 
part in an on-line survey to identify key areas of agreement and disagreement. The 
survey was developed by the TRRIP co-chairs and modified with input from TRRIP 
work group members. In its final version (see Appendix 1), the survey was 
conducted using SurveyMonkey (www.surveymonkey.com). 48 researchers and 
clinicians were invited by email to take part in the survey. Over the 30-day collection 
period, 29 responses (60%), covering 13 countries, were received to the on-line 
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survey; 3 (10%) responses were incomplete. See supplementary information for a 
summary of the responses to individual items. These responses were synthesized 
and refined during subsequent discussions amongst the whole group to derive the 
consensus recommendations for both minimum and optimum criteria. 
 
Third, the working group met to consider and revise criteria for which there was a 
lack of consensus. The revised criteria were circulated to the TRRIP working group 
members, and presented as part of an open workshop at an international meeting in 
the field for further discussion, input and refinement. Finally, consensus was reached 
regarding this publication through review by all authors. 
 
TRRIP meetings 
Criteria were discussed at the Schizophrenia International Research Society biennial 
meeting (2014 and 2016), the American College of Neuropsychopharmacology 
Annual Meeting (2014), and the International Congress On Schizophrenia Research 
(2015), where the open workshop also occurred. 
  
 
Results 
  
Systematic review 
  
2,808 studies were identified of which 42 met selection criteria and were included in 
the review (see figure 1). Operationalized criteria were reported in 21 (50%) studies. 
Only two studies out of 42 used identical criteria to define treatment resistance, and 
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these were from the same research group. In all, 26 studies (62%) required that 
individuals did not respond to at least two adequate treatment trials; there was no 
specification regarding class of antipsychotic in 29 (69%) studies; 24 (57%) studies 
defined an adequate treatment episode as lasting at least 6 weeks; and only 22 
(52%) studies specified dosage in terms of chlorpromazine equivalents while the 
remainder used terms such as “adequate” without providing a dose. 20 (48%) 
studies rated current symptoms using the Brief Psychiatric Rating Scale (18), while 
10 (24%) used the Positive and Negative Syndrome Scale (19). 16 (38%) studies 
employed a prospective phase of supervised treatment as part of the inclusion 
process. Two (5%) of the studies described assessment of past adherence, but 
neither described the methods employed to accomplish this. 
 
 
 
 
Consensus recommendations (Table 2) 
 
The consensus criteria are summarized in table 2 and discussed below. See 
supplementary information for a further discussion of the basis for these 
recommendations.  
 
1. Terminology 
It is recommended that the term “treatment resistant schizophrenia (TRS)” be used 
to describe cases of schizophrenia meeting the criteria outlined below, and that use 
of this term is restricted to patients meeting these criteria. The consistent use of this 
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term will facilitate communication and the identification of relevant literature. In the 
future, if treatments other than antidopaminergic antipsychotics become established 
for schizophrenia, it may be necessary to add treatment specifiers, such as 
“dopamine blocking” treatment resistant schizophrenia. 
  
2. Clinical sub-specifiers 
The initial trials demonstrating the superiority of clozapine for treatment resistance 
were undertaken in patients with a high degree of positive symptoms, and in clinical 
practice this remains the archetypal treatment resistant patient, driven also by the 
fact that current effective treatments for schizophrenia remain limited to positive 
symptoms. However, an increasing amount of research has investigated patient 
groups, that while termed “treatment resistant”, may significantly differ from one 
another in their symptom profile. As a result there is a need for clarity as to patients’ 
clinical profile. A patient’s illness may meet criteria based on overall symptoms, or 
due to specific sub-domains of positive, negative or cognitive symptoms. It may not 
be appropriate to compare patient groups where the illness is predominantly 
resistant to treatment in one domain with those in another domain. In view of this, 
two recommendations are made. First, that the symptom domains used to define 
resistance are made explicit; and, second, that the domain is specified using the 
sub-specifiers: positive, negative or cognitive (the latter contingent on developing 
reliable criteria). Where the patient group is defined as meeting a given threshold of 
positive symptoms this is specified as “treatment resistant schizophrenia- positive 
symptom domain”, and similarly “treatment resistant schizophrenia- negative 
symptom domain”, and “treatment resistant schizophrenia- cognitive symptom 
domain” for the other categories. Where more than one domain is involved, this may 
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be specified, for example as “treatment resistant schizophrenia- positive and 
negative symptom domains” . 
 
3. Symptom thresholds 
3.1 Rating scales 
As can be seen from our summary of clinical guidelines for treatment resistance 
(table 1), the current clinical guidelines for symptom response use terms such as 
“not adequate” that are poorly operationalized. Furthermore, the reliability of these 
definitions for treatment resistance has not been established. In view of this situation, 
a clinical or case note diagnosis of treatment resistance based on clinical guidelines 
cannot be recommended. Instead, it is recommended that a standardized, validated 
symptom rating scale, such as the Positive and Negative Syndrome Scale (17), the 
Brief Psychiatric Rating Scale (18),  the Scale for the Assessment of Negative 
Symptoms SANS (19), or the Scale for the Assessment of Positive Symptoms SAPS 
(20), is used to measure current overall, positive and negative symptom severity. 
 
3.2 Absolute thresholds 
There are two components to the symptomatic assessment of treatment resistance. 
The first is the absolute threshold of current severity. It is conceivable, although in 
practice unlikely, that a patient never has more than mild symptoms, but has not 
shown a response to a series of treatments. Whilst the patient’s symptoms are 
treatment resistant, there are clinical and methodological risks associated with 
including such a patient in studies. Firstly, mild severity on rating scales is at the 
borderline with uncertain symptoms. Given that, even when carefully applied, inter-
rater reliability for rating scales is 0.85-0.9  (21), the measurement error means that 
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there is the risk of including patients with uncertain symptoms. Secondly, the clinical 
risk-benefit balance in patients with mild symptoms is very different from that in 
patients with more severe symptoms, where the severity of the condition provides 
much stronger support for experimental interventions. In view of this, it is 
recommended that the minimum threshold for current symptoms should be at least 
moderate severity, as defined on a standardized rating scale. 
  
By the same token, it is conceivable that a patient could have a rating of moderate 
severity on just one symptom item and no other ratings. Given measurement error, 
there is the risk that this patient’s illness is sub-threshold. Thus, it is recommended 
that the threshold of at least moderate severity is attained for more than one 
symptom in the given domain or, if there is only one symptom, that it should be at 
least severe. These criteria are minimum thresholds that are designed to ensure that 
patients are clearly currently unwell to a degree that would warrant intervention. 
These severity threshold criteria are intended to apply to each domain. So, for 
example, a study of resistant positive symptoms would require at least two positive 
symptoms of moderate or greater severity, or at least one symptom with at least a 
severe rating, and a study of negative symptoms would require at least two negative 
symptoms at moderate or greater severity, or at least one symptom with at least a 
severe rating. A study of both resistant negative and resistant positive symptoms 
would need to meet these criteria in each domain. Of course, a study may recruit 
patients who are much more severely unwell. We do not mean to preclude research 
focusing on patients who are not included in these definitions, but recommend that 
the criteria used are given relative to these criteria so that their differentiating 
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characteristics are clear and reported. This will facilitate future comparisons across 
studies. 
  
It should be relatively straightforward to apply the minimum criteria discussed above 
to positive and negative symptom domains where validated scales exist. However, 
there is no cognitive symptom domain in the most widely used clinical rating scales 
(e.g., PANSS, BPRS, SANS, SAPS) and few if any items cover cognitive symptoms 
in these rating scales. In view of this it is not currently possible to recommend 
threshold criteria for cognitive symptoms. However, a number of current initiatives, 
such as the MATRICS and others (22; 23), aim to develop and validate reliable 
cognitive batteries for the assessment of cognitive symptoms in schizophrenia. 
These will enable the establishment of criteria for treatment resistance in the 
cognitive domain in the future. It should also be noted that factor analyses of rating 
scales have identified other domains, which may be of interest in specific studies. 
We recommend that where these are used they are specified in the same manner as 
the domains listed here.  
 
3.3 Symptom change 
The second component of symptomatic assessment is the determination of response 
to treatment relative to a baseline. Ideally this should be performed prospectively for 
two treatment episodes with different antipsychotic drugs. Whilst this will not always 
be practical, it is recommended that there is at least one prospective evaluation of 
treatment efficacy. If this is not possible, then this should be clearly specified and a 
retrospective assessment of response to treatment obtained as a minimum. A 
change of 20% is the minimum that can be routinely detected clinically (24). 
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Therefore, a reduction less than 20% will correspond to a clinically insignificant 
reduction in symptoms. It could be argued that larger reductions may still not be 
clinically meaningful. However, given that an improvement of ≥20% has been used 
to identify treatment responders (25), requiring <20% reduction ensures the 
treatment resistant group does not overlap with treatment responders. Therefore, it is 
recommended that at the end of the prospective evaluation the absolute symptom 
severity rating criteria above are still met, and that symptom reduction should be 
<20% both for the total rating and specific domain of interest before such a patient 
be included in a prospective treatment trial of treatment-resistant schizophrenia. In 
the event that a patient shows an improvement of ≥20% during the prospective 
observation period, then the patient should be re-evaluated and, if he/she still fulfils 
absolute criteria for treatment-resistance be observed for another prospective 
evaluation period. Only patients who during the prospective observation improve by 
<20% and still fulfill absolute severity thresholds for treatment resistance should be 
called treatment-resistant and included in prospective studies. In contrast, precise 
quantitative assessment is unlikely to be feasible for retrospective evaluation (which 
is exactly why we recommend prospective evaluation of treatment resistance). 
Therefore, for past treatment episodes, we recommend that patients should be rated 
as less than ‘minimally improved’ on the overall change in the Clinical Global 
Impression-Schizophrenia Scale (26). It is recommended that multiple sources of 
information, including patient and caregiver reports, case notes and staff report, are 
used to evaluate past response. Nevertheless, as measurement error is likely to be 
larger in the retrospective evaluation of response to past treatment, in order to be 
conservative, it is recommended that where there is missing information or doubt, 
investigators err on the side of caution and exclude subjects or prospectively 
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evaluate non-response in at least this subgroup. A further important requirement, is 
that investigators ensure that rating scales are adjusted to a baseline of zero. For 
example, a score change from 90 to 60 in the 30-item PANSS, each scored 1-7, 
represents a 50.0% reduction rather than 33.3%. Using a non-zero score for absent 
symptoms with the PANSS will lead to  underestimation of treatment effects when 
percentage change in symptoms is calculated (27). 
 
 
3.4 Functional impact 
It is of course conceivable that a subject has symptoms at threshold severity, but that 
these have little functional impact (28; 29). Thus, in addition to symptom severity it is 
recommended that functional impairment is measured using a recognized, validated 
measure and that this is reported. Scales that just index functioning, such as the 
Role Functioning Scale (30) or the Social and Occupational Functioning Scale 
(SOFAS) (31), are preferred over scales that include symptom assessment as part of 
the measure as symptom severity can strongly influence ratings. To be consistent 
with required symptom thresholds, we propose that there is moderate (eg: score <60 
on SOFAS) or more severe functional impairment. 
 
Distress caused by symptoms is also an important factor to consider. However, due 
to lack of insight associated with schizophrenia (32), some patients may not report 
distress. Furthermore, distress is de facto subjective and difficult to operationalize. In 
view of these factors, it is recommended that subjective distress should not be a 
requirement (although recording or measuring it is desirable to capture patient-
centered outcomes). 
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It should be recognized that symptoms and function may fluctuate as part of the 
natural history of the disorder and that there is an element of measurement error in 
the assessment of symptoms (1; 21). Therefore, it is necessary to establish that 
symptoms have persisted over a reasonable period of time to be clear that a patient 
is truly treatment resistant. It is recommended that a minimum of 12 weeks duration 
of symptoms be used, during which symptoms and functional impairment are of at 
least moderate severity threshold severity and that the minimum duration be clearly 
identified. 
 
4. Characterizing treatment resistance 
4.1 Degree: 
Treatment resistance is mostly treated as a binary variable as a study entry or 
treatment decision criterion in research and clinical practice. This is often necessary 
for research purposes and when making clinical decisions. Clinically, however a 
continuum is apparent (33). As such, carefully characterizing patients will aide a finer 
grained assessment of biological mechanisms or treatment effects in well-defined 
subgroups of patients with treatment resistance. Thus, it is recommended that 
symptom and functional measures are reported in as much detail as possible.  As a 
minimum, this should include positive and negative symptom ratings using a 
validated instrument such as the BPRS, PANSS or SAPS and SANS and a measure 
of functional impairment using a validated measure such as the Role Functioning 
Scale or SOFAS (17; 19; 20; 31; 34; 35).  These measures should also be used to 
characterize change after an intervention, as treatment may affect certain symptom 
domains more than others. This characterization will facilitate research into the 
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continuum of treatment resistance, and enable better comparison between studies 
as well as an estimation of the room for improvement at an individual level.   
 
4.2 Temporal development 
A further issue is when treatment resistance begins. Studies show that treatment 
resistance is present from illness onset in some patients, whilst in others the illness 
shows an initial response to treatment, but subsequently resistance develops (36–
40). From a theoretical perspective, both the mechanisms underlying resistance and 
the therapeutic implications may be different in these two situations: for example, 
clozapine does not show clear superiority over other antipsychotic drugs in non-
treatment resistant first episode patients (41; 42). Whilst the importance of this is not 
clear, to facilitate research into these issues, it is recommended that it is specified 
whether patients have been treatment resistant from within the first year of treatment 
(early-onset treatment resistance), or have developed it during 1 to five years after 
onset of treatment (medium-term onset treatment resistance), or later than five years 
after onset of treatment (late-onset treatment resistance). Ideally, the duration of 
treatment resistance should also be ascertained and reported. Other factors posited 
to be relevant to the pathophysiology of resistance, such as development of 
resistance following relapse and misuse of substances, should be recorded where 
possible (43). It is important to note that duration of treatment resistance relates to 
treatment onset and not illness onset, otherwise it could be confounded by duration 
of untreated psychosis. 
 
5. Defining Adequate Treatment 
5.1 Duration:  
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It could always be argued that a patient may respond if treatment is given for a little 
longer, which, taken to the extreme, leads to the requirement that a patient would 
need to take a given treatment for life to be certain they will not respond. However, 
few non-responders within the first 6 weeks go on to respond at later time points, 
and clinical trials for licensing, which form a large basis of the evidence base, 
generally last 4-6 weeks.(44) Clearly there is the need to balance the risk of false 
positives with practical considerations. Thus it is recommended that each 
antipsychotic treatment episode should have lasted at least 6 weeks, at a 
therapeutic dose (see 5.2), to be deemed ‘adequate’. Thus, given the minimum 
number of different antipsychotic treatment episodes (see 5.3), the minimum 
duration of treatment required is 12 weeks. As outlined below (see 5.5), to rule out 
“pseudo-resistance” due to inadequate treatment adherence, the optimal definition of 
treatment resistance would include at least one failed trial with a long-acting 
injectable antipsychotic (LAI), given for at least 6 weeks after it has achieved steady 
state (generally at least 4 months from commencing treatment) (45; 46). 
 
5.2 Dose:  
For a treatment episode to be deemed therapeutic, the minimum dose of prescribed 
oral or injectable antipsychotic should be the target dose (or mid-point of the target 
dose range) for the acute treatment of schizophrenia given in the manufacturer’s 
summary of product characteristics. If this is not clear or practical, it is recommended 
that a total daily dose equivalent to 600mg of chlorpromazine per day (determined 
using established conversion ratios such as those given in recent papers regarding 
dose conversion (47–49)) is used as the minimum. It is recommended to err on the 
side of a higher minimum dose where there is a range of possibilities. If a trial has to 
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be aborted secondary to intolerability prior to reaching criteria for an adequate 
therapeutic dose maintained for at least 6 weeks, it should not count as a failed 
adequate treatment trial. 
 
5.3 Number of past treatment episodes: 
Failure of at least two adequate treatment episodes with different antipsychotic 
drugs, each meeting the above criteria, is required to establish treatment resistance. 
In some clinical guidelines it is recommended that these trials include different types 
of antipsychotic (such as first- and second-generation drugs) (table 1). However, 
given the overlap in side-effects, efficacy and receptor profiles among currently 
available non-clozapine antipsychotics, the consensus was that the current data do 
not provide unequivocal support for therapeutic categories of different antipsychotic 
drugs (11; 50). There was some disagreement about this conclusion amongst the 
working group members, as olanzapine, risperidone and amisulpride show 
consistent, though small, advantages in meta-analyses of efficacy (51). However, 
consensus was reached that, when considering this from a practical perspective as 
well, specifying particular drug(s) would limit generalizability, not least because a 
given drug may not be readily available in some settings (for example, amisulpride in 
the USA). In view of this, a requirement to use particular categories or drugs (apart 
from clozapine) is not currently recommended. Of course, particular drugs may be 
stipulated in a given study where there is a specific reason to focus on patients who 
have not responded to a certain drug or group of drugs. In practice, many patients 
will have tried a large number of different drugs (16). In view of this, the total number 
of failed adequate antipsychotic treatment trials, the drugs and their dose and route, 
should be ascertained and reported where possible. As mentioned above, a trial with 
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a LAI would be optimal to establish treatment resistance not confounded by 
treatment non-adherence.  
 
It terms of both duration and number of treatment trials, it is necessary to promptly 
optimize treatment, yet to also minimize the risk of prematurely discarding potentially 
effective treatments. Arguments can be made for extending treatment trials, given 
that a proportion of patients appear to show a delayed response (52), conversely it 
can also be argued that treatment with a second non-clozapine antipsychotic after 
initial treatment failure is not warranted, given that response rates seem to be below 
20% (36). The proposed criterion of at least two trials lasting a minimum of 6-weeks 
aims to strike a balance between these two opposing views. 
 
5.4 Clozapine resistant schizophrenia: 
For clarity and due to the specific role of clozapine in the treatment of resistant 
schizophrenia (53–57), failure to respond to clozapine is to be used as a subspecifier 
of treatment resistant illness, i.e., clozapine-resistant schizophrenia. In addition to 
using the mid-dose range as a minimum requirement for an adequate trial, and the 
adherence requirements below (5.5), it is recommended that trough serum levels of 
clozapine are measured on at least two occasions separated by at least a week at a 
stable dose of clozapine. This is important not only to establish adherence, but also 
because of the link between serum levels of clozapine and response (58–62). 
Clozapine levels ≥350 ng/ml (63) constitute an optimum threshold requirement for 
establishing non-response to clozapine treatment. It is strongly recommended that 
levels are used, not least because of the major effect of smoking and gender on 
clozapine’s pharmacokinetics, but where obtaining blood is not possible, a minimum 
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dose of 500mg/day is recommended, unless tolerability issues restrict the dose 
range. This dose is in the middle of the approved dose range for clozapine, and it 
was only at doses of over 400mg a day that clozapine proved superior to other 
antipsychotics in a met-analysis of head-to-head comparisons (64). The duration of 
an adequate trial of clozapine remains to be definitively determined (65). A number 
of studies have recommended trial durations of between 4 and 12 months (66–68). 
Others, however, have suggested that the time course of response is not 
significantly different to non-clozapine antipsychotics (69–71), and the perception of 
a delayed response may primarily be due to the time taken to reach a therapeutic 
level (72).  Due to the lack of clarity as to where to proceed following a failed 
clozapine trial, and the clinical effort required to establish treatment with clozapine, 
we recommend clozapine therapy should be tried for a duration of at least 3 months 
following attainment of therapeutic plasma levels. 
 
5.5 Adherence:  
Due to difficulties with adhering to dosing schedules, lack of illness insight, side 
effect burden, cognitive impairment and other factors, non-adherence is a significant 
problem in the treatment of schizophrenia and is often under-recognized (73–76). 
Non-adherence may be the single largest source of unrecognized error in studies of 
treatment resistance (73). Consequently, it is important to make strenuous efforts to 
determine adherence and apply criteria to exclude poorly adherent subjects who can 
represent false positive “pseudo-resistant” cases. Whilst 100% adherence is rare 
even in clinical trial settings (77; 78), it is necessary to be close to this figure, 
otherwise the study will be of non-adherence rather than of treatment resistance.  
 
Page 28 of 46The American Journal of Psychiatry
Peer Review Only
As a minimum, it is recommended that patients have taken ≥80% of prescribed 
doses at the prescribed dosage level over the required ≥12-week treatment period 
during which the criteria for treatment resistance have persisted. This adherence 
level should be determined by as many sources as feasible, including a minimum of 
two out of: pill counts, dispensing chart review and patient/caregiver report. Sources 
should be specified, but patient report alone is unlikely to be sufficient (34). In 
addition, given that there may still be covert non-adherence, antipsychotic blood 
levels should be determined in all patients taking oral medication on at least one 
occasion (and optimally ≥2 occasions each separated by at least two weeks). 
Because anticipation of blood could encourage an unrepresentative period of 
increased adherence beforehand, tests need to be conducted without advance 
notice of when. Where guidelines (such as the Maudsley Prescribing Guidelines(79)) 
indicate a minimum plasma level associated with response, this should be used as a 
minimum criterion. However, where there is a lack of consensus as to what is a 
therapeutic plasma level, a minimum level will need to be set based on what can be 
expected in people regularly taking the drug at a therapeutic dose (80). 
Nevertheless, unless blood level monitoring is very frequent, covert non-adherence 
is still possible. Thus, where possible, or as a pragmatic and likely superior 
alternative to documenting adequate antipsychotic blood levels on at least one 
occasion, it is recommended that one of the failed treatment episodes involves a LAI; 
or alternatively, that adherence has been monitored via direct observation or with 
technological assistance (81). 
 
 
6. Defining adequate treatment responders 
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Cross-sectional and mechanistic studies will often require a comparator group of 
participants who have shown a good response to treatment. For consistency, the 
same clinical rating scales need to be used to identify this group as are used to 
identify the treatment resistant group. In addition, the criteria need to ensure that 
there is a clear distinction between groups. This precondition requires that the 
criteria make allowance for measurement error, and have clear separation of 
thresholds; to avoid the inclusion of participants rated in a borderline zone who are 
potentially eligible for both groups, dependent on the rater or day that they are rated. 
As such, it is recommended that as an absolute symptom threshold responders 
show no more than mild symptom severity across the symptom items in the 
domain(s) of interest, and have shown this over at least 12 weeks. Where possible it 
is recommended that response is ascertained prospectively over at least 6 weeks 
and defined as at least a 20% improvement in symptom scores for the domain of 
interest as well as meeting the absolute thresholds. Furthermore, there may be 
circumstances, for example studies in first episode patients, where this threshold 
may be of insufficient stringency. In these circumstances investigators may choose 
even more rigorous stability criteria to define adequate treatment response, such as 
having achieved remission, consisting of no more than mild positive and negative 
symptoms for ≥6 months (8), or no symptoms at all. In addition to the symptom 
severity threshold, current functional impairment should not be more than mild (eg 
>60 on SOFAS) in all circumstances (see table 3 for a summary of criteria). 
 
 
Discussion 
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Our review of the criteria currently used to define treatment resistance in clinical 
trials identified significant limitations in published studies. Notably, 50% of studies did 
not use fully operationalized criteria, rendering it impossible to accurately replicate 
these studies. Furthermore, there was wide variation in the criteria used, with 95% of 
studies using different criteria, complicating comparisons across studies. Finally, key 
aspects of determining treatment resistance were not specified in many studies. For 
example, assessment of prior antipsychotic adherence was not specified in 95% of 
studies. These findings indicate a need for criteria that can be used as a benchmark 
for future studies. 
 
We developed criteria to address this need. Across a wide range of areas, there was 
a relatively clear consensus in the working group as to how to best define treatment 
resistant schizophrenia. A summary of the consensus criteria is shown in table 2. 
The criteria we suggest show agreement in a number of domains with those used in 
the majority of previous studies in the literature, in particular the requirements for at 
least two failed treatment trials each of a minimum of six weeks, and the use of 
standardized rating scales (supplementary table 1). However, our recommendations 
differ from approaches used by most studies in the literature to date in several key 
domains. In particular, our recommendations have clear criteria for ensuring 
adequate adherence, and for the inclusion of functional impairment. Furthermore, 
our recommendations include specifiers to characterize the sample, and cover 
reporting standards to aid comparisons across studies. Finally, we recommend a 
lower minimum antipsychotic dose than many early studies required, reflecting the 
recognition in the field that very high doses generally increase the risk of side-effects 
without additional therapeutic benefit. 
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The universal adoption of these consensus criteria would facilitate literature 
searches and meta-analyses as well as help to improve the design of studies. The 
implementation of operationalized criteria should improve the quality and 
reproducibility of research in the area of treatment resistant schizophrenia, both in 
the neurobiological and treatment domains, akin to what has been achieved by 
operationalizing criteria for treatment remission in schizophrenia (8). The next step is 
to utilize the criteria in different research settings to evaluate their ease of use and 
reliability, both within and between raters. We encourage interested researchers to 
help with this effort by forming a Treatment Response and Resistance in Psychosis 
(TRRIP) Trial Network. It should be noted that these criteria are not intended to 
govern clinical practice in the sense that clozapine should only be prescribed to 
patients fulfilling research criteria for treatment resistant schizophrenia. Thus, this is 
not a treatment guideline and the various clinical scenarios that may prompt 
clinicians to use different treatments for patients with schizophrenia are not 
addressed here. 
  
Strengths and Limitations 
The recommendations presented here have been developed through an iterative 
process and in consultation with expert researchers and clinicians from across the 
world. As such, they extend previous recommendations (e.g. (82; 83)) to reflect a 
wide body of opinion, and have been refined to be applicable to a variety of settings. 
Nevertheless, a limitation is that they may not reflect practice or opinion in all 
locations. We have attempted to consult widely to mitigate this issue, and sought to 
produce criteria that are sufficiently representative as to be useful to the field. 
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Furthermore, we have attempted to produce practical criteria that can be easily 
implementable whilst also addressing the limitations of previous approaches. 
 
Although not all invited experts responded to the online survey, they all participated 
in discussions and the development of the consensus criteria. Moreover, whilst the 
survey identified some areas where there were small majorities (see supplementary 
information), subsequent discussions clarified and refined the criteria to enable 
agreement and all participants subscribe to the final criteria presented here. 
Although in clinical care and in treatment guidelines, antipsychotic treatment 
combined with psychosocial strategies is advocated for the optimal care of people 
with schizophrenia, we did not specify a minimum level of “adequate” psychosocial 
interventions as a prerequisite before treatment resistance could be defined. This 
decision was not based on an underestimate of the importance of psychosocial 
treatments, but rather based on the current lack of operationalized criteria for 
determining adequate psychosocial treatment (84). We anticipate revising this 
aspect once initiatives to develop criteria have reported data that will allow for a 
standardized approach. 
  
An important conceptual issue is that the recommendations are based on clinical 
criteria only. The clinical end-point may incorporate multiple pathophysiological 
pathways, which may have different treatment implications. As such, whilst clinical 
criteria are the current state-of-the-art, we anticipate that ultimately the classification 
will be revised and informed by the underlying biology and mechanisms as evidence 
on these emerges (85–87).  
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A further potential issue is that there is likely a continuum of treatment response, and 
that dichotomous categories such as “adequate treatment response” and “treatment 
resistance” are crude and reductionistic. The endorsement of some (established) 
rating scales or some “cutoffs” to achieve this, from a list of many other potentially 
useful options, may be considered as a compromise. Whilst we acknowledge this, 
clinicians and patients have to make choices about whether to continue with a given 
treatment, and research studies require patients to be randomized to a given 
treatment. In this context, the categorisation we propose aims to prioritize specificity 
over sensitivity and should help facilitate both clinical care and research decisions.  
 
The criteria recommended here reflect a consensus on the balance between 
practical considerations, the risk of false positives and the potential to translate 
findings derived from studies into clinical practice. It is acknowledged that alternative 
cut-offs may be more appropriate in specific studies, but we recommend that these 
criteria are specified in reference to the benchmarks outlined here, so that it is clear 
in what way the criteria are different. 
 
Finally, we have codified the concept that treatment resistance may develop at 
different stages of the illness, or be present from illness onset. Clinically, it is clear 
that there are some patients who initially experience a good response to 
antipsychotic treatment and treatment resistance later develops, whilst others have 
little or no response from illness onset (36–40). This is of considerable potential 
clinical and mechanistic importance.  However, despite this wide-spread clinical 
observation, there is relatively little research evidence on this issue (36–40). Our 
categorisation does introduce boundary issues, particularly between early and late 
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treatment resistance, where it may be argued that there is likely to be little difference 
between a patient who develops treatment resistance after 4 years of treatment, and 
a patient who develops it after 5 years of treatment. 
 
However, practical considerations required a cut-off that would be easy to apply and 
that reflected widespread clinical and research definitions of the early course of 
schizophrenia, which include the first five years following illness onset (88; 89). It is 
intended that the criteria will stimulate research into whether there are differences 
between patients who develop treatment resistance early, late or from illness onset, 
and clarify the reporting of studies. 
 
Conclusions and future directions 
Treatment resistant schizophrenia is a major clinical problem, and clinical guidelines 
throughout the world recommend specific treatments for affected individuals (5–7). A 
wide variety of criteria have been applied in research studies. As a consequence, 
clinical guidelines based on these studies use imprecise or inconsistent definitions 
that are likely to include patients with very different clinical characteristics to the 
patients included in the clinical trials on which the guidelines are based. 
Furthermore, the variation in criteria limits comparison of studies, complicates the 
interpretation of findings, and may contribute to the failure to replicate findings (12; 
13). 
 
We have developed operationalized criteria to address this issue based on a process 
of wide consultation and refinement, involving expert researchers and clinicians, 
scientists from the pharmaceutical industry and other specialists who are active in 
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the field. It is intended that they provide benchmarks to aid study design and 
reporting as well as research into the neurobiology of more homogeneously defined 
subgroups and the development of novel treatment strategies. We acknowledge that 
some criteria may not be appropriate for certain questions or studies. It is not 
intended that these criteria prevent studies using alternative criteria, but where 
researchers use alternative criteria, we strongly recommend that the differences are 
indicated (and justified) against the benchmark given in table 2. 
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Figure 1: Summary of criteria used in clinical trials of treatment resistant 
schizophrenia 
NS – Not specified. CPZ – Chlorpromazine equivalents 
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Guideline 
Requirements of previous treatment Severity of 
illness 
Other Minimum 
number of 
failed APs 
Specified AP Adequate 
treatment 
episode 
duration 
Dose 
APA(6) 2 “At least one of which is 
a second-generation 
AP” 
≥6 weeks Therapeutic range “a clinically 
inadequate response” 
“and for patients with 
persistent suicidal 
ideation or behaviour 
that has not 
responded to other 
treatments” 
Nil 
RANZCP (90) 2 Recommends both first 
and second trial to be of 
an atypical 
6-8 weeks Dosages 
specified for 
“Poor response” “If poorc adherence, or 
persistent suicide risk, 
positively offer trial of 
clozapine.” 
BAP(91) 2 “One of the trials should 
be of an antipsychotic 
with an established, 
favourable, efficacy 
profile in comparison 
with other 
antipsychotics” 
‘Adequate’ ‘Adequate’ ‘schizophrenic illness 
has shown a poor 
response to, or 
intolerance of the 
neurological side 
effects of [previous 
treatment]’ 
“Poorcadherence and 
csubstance use should 
be excluded as causes 
of the cpoor response 
to AP “ 
IPAP(92) 2 “ca typical or, if not 
available a trial of 
haloperidol, 
chlorpromazine or other 
typical antipsychotic” 
4-6 weeks ‘Adequate’ Psychosis or mod-to-
severe TD or tardive 
dystonia after 
adjusting dose” 
 
Nil 
Maudsley (79) 2 Consider use of either 
first generation or 
second generation AP 
2-3 weeks for 
trial of first  AP in 
FEP.  6 week 
trial for 
subsequent  2nd 
AP before 
clozapine. 
At least minimum 
effective dose, 
then titrated to 
response 
Not specified Nil 
MOHS(93) 2 No Adequate Adequate “illness has not 
responded 
adequately to 
treatment” 
2 trials should be given 
“sequentially” 
NICE(5) 2  “One of the drugs 
should be a non-
clozapine second-
generation AP” 
Not specified Adequate “illness has not 
responded 
adequately to 
treatment” 
2 trials should be given 
“sequentially” 
WFSBP(7) 2 “one of which should 
be an atypical 
antipsychotic” 
6-8 weeks Recommended 
dosage 
no improvement 
at all or only 
insufficient 
improvement in the 
target symptoms 
Compliance should be 
ensured, if necessary 
by checking drug 
concentrations 
Table 1. Recommendations for when to consider that a patient’s illness is treatment 
resistant used in international guidelines 
AP – Antipsychotic; APA – American Psychiatric Assocation; BAP – British Association for Psychopharmacology; FEP – First 
Episode Psychosis; IPAP - The International Psychopharmacology Algorithm Project; MOHS – Ministry of Health Singapore; 
NICE – National Institute for Clinical Excellence; RANZCP - Royal Australian and New Zealand College of Psychiatrists; 
WFSBP - World Federation of Societies of Biological Psychiatry. 
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Domain Subdomain Minimum Requirement Optimum Requirement 
Current 
symptoms 
Assessment Interview using standardised rating scale 
(e.g., PANSS, BPRS, SANS, SAPS) 
Prospective evaluation of treatment 
using standardised rating scale 
Severity At least moderate severity At least moderate severity and <20% 
symptom reduction during prospective 
trial/observation ≥6 weeks 
Duration ≥12 weeks ≥12 weeks. Specify duration of 
treatment resistance. 
Subjective 
distress 
Not required                                         Not required                                         
Functioning At least moderate functional impairment 
measured using a validated scale (eg z) 
At least moderate functional impairment 
measured using a validated scale (eg 
SOFAS) 
Adequate 
treatment 
Assessment 
of past 
response 
Information to be gathered from 
patient/carer reports, staff and case 
notes, pill counts and dispensing charts. 
Information to be gathered from 
patient/carer reports, staff and case 
notes, pill counts and dispensing charts. 
Duration ≥6 weeks at a therapeutic dose                                                                  
Record minimum and mean (sd) duration 
for each treatment episode 
≥6 weeks at a therapeutic dose Record 
minimum and mean (sd) duration for 
each treatment episode 
Dose Equivalent to ≥600mg chlorporamzine 
per day1 
Record minimum and mean (sd) dose for 
each drug 
Equivalent to ≥600mg chlorporamzine 
per day1  
Record minimum and mean (sd) dose 
for each drug 
Number of 
anti- 
psychotics 
≥2 past adequate treatment episodes 
with different antipsychotic drugs 
Specify median number of failed 
antipsychotic trials. 
≥2 past treatment episodes with 
different antipsychotic drugs and at 
least one utilizing a long-acting 
injectable antipsychotic (for at least 4 
months). Specify median number of 
failed antipsychotic trials. 
Current 
Adherence 
≥80% of prescribed doses taken. 
Adherence should be assessed using  ≥ 
2 of pill counts, dispensing chart reviews 
and patient/carer report. Antipsychotic 
plasma levels monitored on at least one 
occasion. 
Specify methods used to establish 
adherence. 
As for minimum criteria and additionally 
trough antipsychotic serum levels 
measured on at least two occasions 
separated by at least two weeks 
(without prior notification of patient).  
Symptom Domain Positive/Negative/Cognitive 
Time course Early-onset (within 1 year of treatment onset)/ Medium-term onset 
(within >1-5 years of treatment onset)/ Late-onset (after >5 years of 
treatment onset) 
Ultra-treatment 
resistant: clozapine 
Meets the criteria for treatment resistance above plus failure to 
respond to adequate clozapine treatment2  
Table 2: Consensus criteria for assessment and definition of treatment resistant 
schizophrenia 
BPRS- Brief Psychiatric Rating Scale; CGI-S-TRS - Clinical Global Impressions-Severity Treatment Resistant Schizophrenia 
scale; PANSS- Positive and Negative Syndrome Scale; ECT - Electro-convulsive therapy; SANS - Scale for the Assessment of 
Negative Symptoms; SAPS - Scale for the Assessment of Positive Symptoms; SOFAS- Social and Occupational Functioning 
Scale 
1based on established conversion criteria(47–49) 
2See section 5.5 
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Treatment 
Response 
Symptom 
severity 
Symptoms rated at no more than mild severity 
Duration Response sustained for a minimum of 12 weeks 
Functioning Mild or better functioning on a standardised scale (e.g. 
SOFAS) 
 
Table 3: Criteria for establishing a group of patients with adequate treatment response
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